BRAIN Biotech AG

BATS-CHIXE:BNND Stock Report

Market Cap: €130.2m

BRAIN Biotech Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of BNND?
Owner TypeNumber of SharesOwnership Percentage
Institutions5,027,61923%
General Public7,643,92835%
Private Companies9,175,94842%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 64.84% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
36.4%
MP Beteiligungs-Gmbh
7,952,488€47.4m0%no data
5.6%
Service Innovation Group GmbH
1,223,460€7.3m0%no data
3.9%
SPSW Capital GmbH
852,052€5.1m0%1.18%
3.2%
Universal-Investment-Gesellschaft Mit BeschrÄNkter Haftung
698,531€4.2m-49.5%0.03%
2.89%
LLB Swiss Investment AG
630,583€3.8m0%0.95%
2.37%
Medical Strategy GmbH, Asset Management Arm
518,736€3.1m0%0.22%
1.52%
Deka Investment GmbH
333,151€2.0m0%no data
1.37%
Deutsche Asset & Wealth Management
299,586€1.8m0%no data
1.34%
Joh. Berenberg, Gossler & Co. KG, Asset Management Arm
292,370€1.7m0%0.05%
1.21%
FPM Frankfurt Performance Management AG
265,000€1.6m0%2.27%
1.12%
MEAG MUNICH ERGO Asset Management GmbH
245,639€1.5m0%0.34%
0.7%
KBC Asset Management NV
152,499€908.9k0%no data
0.55%
Baring Asset Management Limited
120,000€715.2k-6.25%0.01%
0.38%
UBS Asset Management
82,967€494.5k0%no data
0.36%
AXA Investment Managers S.A.
79,000€470.8k0%no data
0.36%
Credit Suisse Asset Management (Switzerland)
78,221€466.2k-8.83%no data
0.33%
KD Skladi druzba za upravljanje, d.o.o.
73,013€435.2k0%0.09%
0.33%
Lupus Alpha Asset Management GmbH
71,832€428.1k0%0.04%
0.21%
Sparkasse Mittelthüringen, Asset Management Arm
46,398€276.5k0%0.29%
0.2%
Esaliens TFI S.A.
42,613€254.0k0%0.11%
0.14%
MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH
29,824€177.8k0%no data
0.11%
LaRoute GmbH
23,500€140.1k0%0.4%
0.092%
Spirit Asset Management SA
20,000€119.2k0%0.14%
0.078%
Kirix VermÖGensverwaltung Ag
17,000€101.3k0%0.03%
0.077%
SP-Rahastoyhtiö Oy
16,800€100.1k0%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2022/12/19 11:13
End of Day Share Price 2022/09/21 00:00
Earnings2022/06/30
Annual Earnings2021/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BRAIN Biotech AG is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Laura Lopez PinedaBaader Helvea Equity Research